News Updates
Research Landscape of Stem Cell Applications in Musculoskeletal Tissue: A Scoping Review
Stem cell therapy represents an intrinsic part of regenerative medicine, with expanding applications in orthopedic and musculoskeletal research. Although studies span from small-animal models to early-phase clinical trials, the field remains fragmented, with wide variation in stem cell types, delivery methods, and target tissues.
Source: MDPI
Comparative Efficacy of Different Doses of Mesenchymal Stem Cells Derived from Different Tissue Sources for Knee Osteoarthritis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
Knee osteoarthritis (KOA) remains a leading cause of disability, and mesenchymal stem cells (MSCs) show potential for KOA treatment. However, existing studies demonstrate conflicting results on the optimal dose and tissue source of MSCs for KOA treatment. This gap limits evidence-based treatment decisions.
Source: PubMed Central
Chondrogenesis of Peripheral Blood-Derived Mesenchymal Stromal Cells
Articular cartilage, a highly specialised and avascular tissue, exhibits limited regenerative potential following trauma or degenerative conditions such as osteoarthritis (OA). Conventional surgical interventions, including microfracture and autologous chondrocyte implantation (ACI), have shown limited long-term efficacy due to donor site morbidity and restricted cell proliferation. In this context, mesenchymal stromal cells (MSCs) have emerged as a promising alternative owing to their multipotency, self-renewal capacity, and low immunogenicity. While bone marrow (BM) remains the traditional source of MSCs, recent studies have reported that peripheral blood-derived mesenchymal stromal cells (PB-MSCs) may possess chondrogenic, osteogenic, and adipogenic potential comparable to that of BM-derived MSCs.
Source: PubMed
Biological Treatment in Meniscus Injury
Meniscal injuries, common in sports, often cause knee pain and instability. The meniscus plays a key role in pressure distribution and joint stability, making its repair essential. Treatments range from conservative approaches to surgical interventions, with growing interest in biological factors such as growth factors, mesenchymal stem cells, platelet-rich plasma, fibrin clot, and tenocyte to enhance healing. This review compares the effects of these biological agents in meniscal repair, examining their mechanisms, limitations, and clinical outcomes.
Biologics for bone regeneration: advances in cell, protein, gene, and mRNA therapies
Bone fractures represent a significant global healthcare burden. Although fractures typically heal on their own, some fail to regenerate properly, leading to nonunion, a condition that causes prolonged disability, morbidity, and mortality. Biologic therapies have emerged as promising tools to enhance bone regeneration by leveraging the body's natural healing processes. This review explores the critical role of conventional and emerging biologics in fracture healing.
Source: Nature
Mesenchymal Stem Cell-Derived Extracellular Matrix for Musculoskeletal Tissue Regeneration
Mesenchymal stem cell-derived extracellular matrix (mECM) is increasingly recognized in tissue regeneration due to its high biocompatibility, controllability, and customizability. In musculoskeletal diseases, mECM provides a 3D scaffold mimicking the natural cellular environment and contains bioactive components regulating cell behavior and fate to promote tissue regeneration and repair. This review summarizes the preparation methods and composition of mECM, its effects on regulating cell behavior, and its applications in bone, cartilage, muscle, nerve, and blood vessel repair.
Source: Nature
Stem Cell Therapy for Spinal Cord Injury: Lessons from Japan`s Experiment in Regulatory Deregulation
Stem cell-based therapies for spinal cord injury (SCI) have generated substantial global interest; however, no regenerative treatment has yet demonstrated sufficient efficacy to achieve full regulatory approval in major jurisdictions. In Japan, an expedited regulatory framework enabled the conditional approval of Stemirac, an autologous mesenchymal stem cell therapy for SCI, based on limited and uncontrolled clinical evidence. This Perspective examines the scientific, methodological, and ethical implications of that decision. Focusing on trial design, outcome assessment, extensive public and media attention during the confirmatory trial period, and downstream societal consequences, we explore how premature commercialization under public reimbursement may compromise scientific rigor and erode public trust.
Source: ScienceDirect
